Alluzience (Botulinum Toxin Type A Solution)

Due to the innovative liquid formulation process of Alluzience, the product has a shelf life of less than 12 months from the date of manufacture. The formulation remains stable for the duration of this shelf life, without compromising the efficacy or safety of the product, when stored in the conditions as stated on label.

Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.

We provide Galderma (U.K.) Limited with certain information on who has purchased their products through this website for consumer service/support and safety purposes. A copy of Galderma’s Privacy Notice explaining how your data will be collected, used, and disclosed by Galderma can be found here https://tinyurl.com/galdermaprivacy

Adverse events should be reported

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Ireland, suspected adverse events can be reported via HPRA Pharmacovigilance, www.hpra.ie

Adverse events should also be reported to Galderma (UK) Ltd.

E-mail: Medinfo.uk@galderma.com Tel: +44 (0) 300 3035674